Recarbrio™ (imipenem/cilastatin/relebactam) – New drug approval
July 17, 2019 - The FDA announced the approval of Merck’s Recarbrio (imipenem/cilastatin/relebactam), in patients 18 years of age and older who have limited or no alternative treatment options, for the treatorment of complicated urinary tract infections (cUTI) or complicated intra-abdominal infections (cIAI).
Top